Clinical trials: Disorder of Upper Respiratory System
Upper Resp Tract Infection, Rhinitis Acute
Evaluation of a Hypertonic Seawater Aerosol Therapy Solution in Adults and Children
The purpose of this study is to evaluate the tolerance, the performance and safety of this device, 22‰ Hypertonic seawater aerosol therapy solution in unidose container, to treat adult and peadiatric patients with of upper…
- Conditions
- Upper Resp Tract Infection, Rhinitis Acute, Rhinopharyngitis, Cold Symptom
- Trial name
- AIR (NCT07267689)
- Testing
- Treatment (22‰ Hypertonic seawater aerosol therapy solution)
- Where
- 4 sites in Poland
- Volunteers
- 110 people
- Sponsor
- Laboratoires Gilbert
Human Influenza
Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, in Healthy Adults Aged 18 Years and Above
The present study is designed to confirm the safety and immunogenicity of trivalent, surface antigen, inactivated influenza vaccine in 2 age cohorts: 18 to ≤60 years and ≥61 years.
- Trial name
- NCT01879553
- Testing
- TIV
- Where
- Belgium
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Upper Respiratory Tract Infection
Pharmacokinetics of Adrenaline After Administration of ARS -1 in Subjects With Upper Respiratory Tract Infection
This is a Phase 1, single-dose, two-period study that will consist of a combined screening and baseline period and an open-label treatment period.
- Trial name
- NCT04930900
- Testing
- ARS-1 with URTI, ARS-1 without URTI
- Where
- Australia
- Volunteers
- 15 people
- Sponsor
- ARS Pharmaceuticals, Inc.
Alopecia Areata, Depressive Episode
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and…
- Conditions
- Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04239521
- Testing
- Exposure of interest (studies 2 & 3).
- Where
- United Kingdom
- Volunteers
- 51,955 people
- Sponsor
- Momentum Data
Controlled Asthma
Modelling of the Upper Airway in Children With Controlled Asthma
Asthma in children is recognized as a disease area with a high medical need. As the investigators move into this field it is necessary to improve the investigators knowledge of upper airway anatomical structure in paediatric…
- Trial name
- NCT01594151
- Testing
- Cone Beam Computed Tomography
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- FLUIDDA nv
Pneumonia, Pneumococcal
Safety Study of 15-Valent Pneumococcal Conjugate Vaccine in Healthy Volunteers Aged Above 2 Months
The purpose of this study is to evaluate safety of 15-Valent Pneumococcal Conjugate Vaccine in healthy volunteers aged above 3 Months.
- Trial name
- NCT04108845
- Testing
- 15-Valent Pneumococcal Conjugate Vaccine
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
COVID-19, SARS-CoV-2
A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above
Approximately 28,000 subjects will be enrolled in this trial. Eligible subjects will be stratified by age (<60 years of age and ≥60 years of age, the proportion of elderly people ≥60 years old is planned to be ≥25%) and randomly…
- Trial name
- NCT04847102
- Testing
- SARS-CoV-2 mRNA Vaccine
- Where
- 12 sites in Indonesia, Mexico
- Volunteers
- 28,000 people, healthy volunteers welcome
- Sponsor
- Walvax Biotechnology Co., Ltd.
Influenza
A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults
This study is designed to test the immunogenicity and reactogenicity of the Fluarix™/Influsplit SSW® influenza vaccine containing the influenza strains recommended for the 2010-2011 season.
- Trial name
- NCT01144299
- Testing
- Fluarix™/Influsplit SSW®
- Where
- 6 sites in Germany
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity, Safety and Tolerability of a Trivalent Subunit Inactivated Vaccine in Healthy Subjects 50 Years and Above
Demonstrate non-inferiority of the post-vaccination (Day 22) Hemagglutination inhibition (HI) Geometric Mean Titers (GMTs) of trivalent, inactivated, subunit influenza vaccine (TIV) over the corresponding GMTs of the comparator…
- Trial name
- NCT01867021
- Testing
- Fluvirin(TIVf), Agriflu (TIV)
- Where
- 25 sites in Czechia, Philippines and 2 more
- Volunteers
- 2,902 people, healthy volunteers welcome
- Sponsor
- Novartis
Influenza, Human, Infections
Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults
This Phase 1, randomized, observer-blind, dose-ranging clinical study is evaluating 6 different formulations of MF59-adjuvanted and non-adjuvanted H2N3 influenza vaccine.
- Conditions
- Influenza, Human, Infections, Respiratory Tract Infections, Virus Diseases
- Trial name
- NCT05875961
- Testing
- Low dose A/H2N3c + standard dose MF59, Intermediate dose A/H2N3c + standard dose MF59, High dose A/H2N3c + standard dose MF59
- Where
- 7 sites in United States, Philippines
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Seqirus
COVID-19
The Immunogenicity, Safety, and Effectiveness of the COVID-19 Inactivated Vaccine
To fast respond the coronavirus disease of 2019 (COVID-19) pandemic, the Indonesian government has launched "Vaksinasi Gotong Royong" (a mutual cooperation vaccination program) in which any company/legal entity/business entity…
- Trial name
- NCT05126550
- Testing
- SARS-CoV-2 vaccine (Vero cell) inactivated
- Where
- 4 sites in Indonesia
- Volunteers
- 435 people, healthy volunteers welcome
- Sponsor
- PT. Kimia Farma (Persero) Tbk
Upper Respiratory Tract Infections
LiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Media
Acute respiratory tract infections (ARTIs), such as acute rhinosinusitis (ARS) and acute otitis media (AOM), are common worldwide and caused by viruses or bacteria entering the body through the mouth and nose.
- Trial name
- NCT05804123
- Testing
- 0.9% NaCl physiological saline Nasal-spraying, LiveSpo Navax®, Augmentin 500Mg Tablet
- Where
- Vietnam
- Volunteers
- 175 people
- Sponsor
- Anabio R&D
COVID-19
Homologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine
Open-label, prospective intervention study of IndoVac® as a single, homologous booster dose
- Trial name
- NCT05933278
- Testing
- SARS-CoV-2 Subunit Recombinant Protein Vaccine
- Where
- Indonesia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Influenza
Study to Evaluate the Safety and Immunogenicity of Fluarix™ 2006/2007 in Adults Aged 18 Years or Above
Vaccination is currently the most effective mean of controlling influenza and preventing its complications and mortality in persons at risk.
- Trial name
- NCT00345904
- Testing
- Fluarix
- Where
- 4 sites in Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Obstructive Sleep Apnea
Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED)
The SEED study is designed to assess the safety and efficacy for Obstructive Sleep Apnea (OSA) of 3 escalating dose combinations of atomoxetine with AD313 compared to baseline and to atomoxetine alone.
- Trial name
- SEED (NCT05101122)
- Testing
- Dosing 1: Atomoxetine, AD313
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Apnimed
COVID-19 Pandemic
A Phase I/II Clinical Trial in Healthy People Aged 18 Years and Above
This clinical trial is a phase I/II clinical trial to evaluate the safety, immunogenicity and immune persistence of COVID-19 mRNA vaccine in healthy people aged 18 years and above.
- Trial name
- NCT05144139
- Testing
- COVID-19 mRNA vaccine
- Where
- Laos
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Stemirna Therapeutics
Rhinovirus, Upper Respiratory Tract Infection
A Study of Vapendavir Treatment of Hematopoietic Stem Cell Transplant Subjects With Symptomatic Rhinovirus Infection
This is a randomized, double-blind, placebo-controlled study of vapendavir treatment of laboratory-confirmed and symptomatic HRV infection of the upper respiratory tract in allogeneic and autologous stem cell transplant subjects.
- Trial name
- NCT03024177
- Testing
- Vapendavir
- Sponsor
- Vaxart
Acute Upper Respiratory Tract Infections, Bronchitis
Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of "AG NPP709 Syrup"
The purpose of this study is to assess therapeutic confirmation of AG NPP709 syrup to evaluate the safety and efficacy in patients with acute upper respiratory tract infection and chronic inflammatory bronchitis.
- Trial name
- NCT01151202
- Testing
- AG NPP709syrup
- Where
- 6 sites in South Korea
- Volunteers
- 236 people
- Sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
Respiratory Syncytial Virus Infections
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above
The aim of this study is to demonstrate the non-inferiority (NI) of the immune response and evaluate safety of RSVPreF3 older adults (OA) investigational vaccine in adults 50-59 years of age (YOA), including those who are at…
- Trial name
- NCT05590403
- Testing
- RSVPreF3 OA investigational vaccine
- Volunteers
- 1,544 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Common Cold, Upper Respiratory Tract Infection (URTI)
Effect of Immune X on Common Cold Incidence in Healthy Adults
The goal of this clinical trial is to learn if Immune X can help prevent common cold events in healthy adults who have a history of upper respiratory tract infections.
- Trial name
- CELFI (NCT07787130)
- Testing
- Immune X
- Where
- France
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Givaudan France Naturals